Search results
Showing 76 to 90 of 149 results for multiple sclerosis
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
This advice has been updated and replaced by NICE guideline NG220.
This guidance has been updated and replaced by NICE guideline NG220.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Discontinued Reference number: GID-TA11357
Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)
This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.
Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
This guidance has been updated and replaced by NICE technology appraisal guidance 616.
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]
In development Reference number: GID-TA11750 Expected publication date: TBC
This guidance has been updated and replaced by NICE interventional procedures guidance 640.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (HTG334)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.